Advanced breast cancer

1 paper

Human trial1

Trial sponsors

Pierre Fabre Medicament
Company1 trialPhase 31,004 people
AstraZeneca
Company1 trialPhase 3788 people
Daiichi Sankyo
Company1 trialPhase 3200 people
Bristol Myers Squibb
Company3 trialsPhase 2386 people
Pfizer
Company3 trialsPhase 2300 people
Novartis Pharmaceuticals Corporation
Company2 trialsPhase 2251 people
Relay Therapeutics
Company2 trialsPhase 1971 people
CSPC ZhongQi Pharmaceutical Technology
Company1 trialPhase 1382 people

Funding

1 grant since 2023

National Cancer InstituteUS$349.3k

Pre-analytical factors affecting ctDNA analysis in early and locally advanced breast cancer
National Cancer InstituteUniversity of Wisconsin-madisonUS$349.3k2019–2025

Latest

1 in 12 months

Contemporary Clinical Trials7 Oct

Breast cancer screening based on clinical breast examination performed by community health workers: study protocol for a randomized clinical trial. ITABERAÍ Project / ReBEC n° RBR-39vm2nd

Trial protocolBreast cancer

The Lancet Oncology16 Jun

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Randomised trial in 719 peopleBreast cancer

The New England Journal of Medicine7 Dec

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Randomised trial in 724 peopleBreast cancer